98,375 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by Boussard & Gavaudan Investment Management LLP

Boussard & Gavaudan Investment Management LLP purchased a new stake in Surmodics, Inc. (NASDAQ:SRDX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 98,375 shares of the company’s stock, valued at approximately $3,899,000.

Other institutional investors have also recently made changes to their positions in the company. Modus Advisors LLC acquired a new position in shares of Surmodics in the fourth quarter worth approximately $40,000. Quest Partners LLC lifted its position in shares of Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after purchasing an additional 1,071 shares during the period. R Squared Ltd acquired a new position in shares of Surmodics in the 4th quarter worth approximately $55,000. SG Americas Securities LLC boosted its stake in shares of Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after purchasing an additional 1,255 shares during the last quarter. Finally, Algert Global LLC increased its position in shares of Surmodics by 29.9% during the third quarter. Algert Global LLC now owns 17,820 shares of the company’s stock worth $691,000 after buying an additional 4,098 shares during the period. Institutional investors own 96.63% of the company’s stock.

Analyst Ratings Changes

SRDX has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a “hold” rating on the stock. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Finally, Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Surmodics presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

Shares of SRDX opened at $30.61 on Friday. The stock has a market cap of $437.60 million, a P/E ratio of -30.31 and a beta of 1.19. The business’s fifty day moving average is $32.99 and its 200 day moving average is $36.83. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. Surmodics, Inc. has a 12-month low of $25.17 and a 12-month high of $42.44.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Sell-side analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).